Vortioxetine Set For Japan Filing But Prospects Limited?
Executive Summary
Positive results from a Japanese trial of Takeda/Lundbeck’s vortioxetine pave way for a planned approval filing in the country this year, but how might drug fare in the market?
You may also be interested in...
Shionogi Deal Opens Asia To Sage’s Fast-Acting Antidepressant
Japan’s Shionogi has gained selected Asian rights to Sage’s promising fast-acting depression drug, in a deal worth up to $575m to the US company.
China Approves Lundbeck Antidepressant In Year-End Dash
China FDA greenlights Lundbeck's Brintellix for severe depression, and more new drug approvals may be on the way. Physician education will be key for Brintellix, given relatively low number of psychiatrists in China.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.